The results also emphasized that utilizing both epithelial (EpCAM) and mesenchymal (vimentin) antibodies with the lateral magnetophoretic microseparator significantly enhanced CTC isolation efficiency for both prostate and pancreatic cancer patients. This evidence concerns the gene EPCAM and pancreatic neoplasm.